These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29416923)

  • 21. Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics.
    Saifi MA; Sathish G; Bazaz MR; Godugu C
    Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188895. PubMed ID: 37037389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of an Amphiphilic iRGD Peptide and Self-Assembling Nanovesicles for Improving Tumor Accumulation and Penetration and the Photodynamic Efficacy of the Photosensitizer.
    Jiang Y; Pang X; Liu R; Xiao Q; Wang P; Leung AW; Luan Y; Xu C
    ACS Appl Mater Interfaces; 2018 Sep; 10(37):31674-31685. PubMed ID: 30133254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
    Hu C; Chen X; Huang Y; Chen Y
    Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. iRGD Tumor-Penetrating Peptide-Modified Nano-Delivery System Based on a Marine Sulfated Polysaccharide for Enhanced Anti-Tumor Efficiency Against Breast Cancer.
    Chen B; Liu X; Li Y; Shan T; Bai L; Li C; Wang Y
    Int J Nanomedicine; 2022; 17():617-633. PubMed ID: 35173433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-Penetrating Peptide-Functionalized Redox-Responsive Hyperbranched Poly(amido amine) Delivering siRNA for Lung Cancer Therapy.
    Guo Z; Li S; Liu Z; Xue W
    ACS Biomater Sci Eng; 2018 Mar; 4(3):988-996. PubMed ID: 33418781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy.
    Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
    Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells.
    Zhang L; Xing Y; Gao Q; Sun X; Zhang D; Cao G
    Biomed Pharmacother; 2017 Sep; 93():1136-1143. PubMed ID: 28738522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
    Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
    Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly Stable Fluorinated Nanocarriers with iRGD for Overcoming the Stability Dilemma and Enhancing Tumor Penetration in an Orthotopic Breast Cancer.
    Ma S; Zhou J; Zhang Y; He Y; Jiang Q; Yue D; Xu X; Gu Z
    ACS Appl Mater Interfaces; 2016 Oct; 8(42):28468-28479. PubMed ID: 27712073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-administration of biocompatible self-assembled polylactic acid-hyaluronic acid block copolymer nanoparticles with tumor-penetrating peptide-iRGD for metastatic breast cancer therapy.
    Deng C; Xu X; Tashi D; Wu Y; Su B; Zhang Q
    J Mater Chem B; 2018 May; 6(19):3163-3180. PubMed ID: 32254351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy.
    Lin C; Tong F; Liu R; Xie R; Lei T; Chen Y; Yang Z; Gao H; Yu X
    Acta Pharm Sin B; 2020 Dec; 10(12):2348-2361. PubMed ID: 33354506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus.
    Al-Zaher AA; Moreno R; Fajardo CA; Arias-Badia M; Farrera M; de Sostoa J; Rojas LA; Alemany R
    Mol Ther Oncolytics; 2018 Mar; 8():62-70. PubMed ID: 29888319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis.
    Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J
    Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and evaluation of tumour microenvironment response multistage nanoparticles for epirubicin delivery and deep tumour penetration.
    Dai J; Han S; Ju F; Han M; Xu L; Zhang R; Sun Y
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):860-873. PubMed ID: 29771149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
    Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
    Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.
    Puig-Saus C; Rojas LA; Laborda E; Figueras A; Alba R; Fillat C; Alemany R
    Gene Ther; 2014 Aug; 21(8):767-74. PubMed ID: 24942629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased antitumor activity of tumor-specific peptide modified thymopentin.
    Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
    Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.
    Zuo H
    J Oncol; 2019; 2019():9367845. PubMed ID: 31346334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. iRGD as a tumor‑penetrating peptide for cancer therapy (Review).
    Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J
    Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.